EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice

Qamar Shubbar, Aminah Alchakee, Khaled Walid Issa, Abdul Jabbar Adi, Ali Ibrahim Shorbagi, Maha Saber-Ayad

Frontiers in Pharmacology · 14.02.2024 · 15

DOI: 10.3389/fphar.2024.1326776 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.02.2024. Verfasst von Qamar Shubbar und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CYP2C19 gene is frequently included in different pharmacogenomic panels tested in clinical practice, due to its involvement in the metabolism of a myriad of frequently prescribed medications. Accordingly, CYP2C19 genotyping can promote precise therapeutic decisions and avoid the occurrence of significant drug-drug-gene interactions in the clinical setting. A comprehensive examination of the role of the CYP2C19 gene in real-world medical settings is presented in this review. This review summarizes the most recent information on how genetic variants in CYP2C19 affect drug metabolism and therapeutic outcomes. It goes into the wide range of CYP2C19 phenotypes, with different degrees of metabolizing activity, and their implications for customized medication response through a review of the literature. The review also analyzes the clinical significance of CYP2C19 in several medical specialties, including cardiology, psychiatry, and gastro-enterology clinics, and illuminates how it affects pharmacological efficacy, safety, and adverse effects. Finally, CYP2C19 -supported clinical decision-making is outlined, highlighting the possibility of improving therapeutic outcomes and achieving more affordable treatment options, a step towards optimizing healthcare provision through precision medicine.

Schlagwörter

Stichwörter der Autor:innen

CPICCYP2C19ethnic variationgene polymorphismgentotypepharmacoeconomicpharmacogeneticsprecision medicine

Autor:innen und Institutionen

  • College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
  • Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.

Zitieren

APA

Shubbar, Q., Alchakee, A., Issa, K. W., Adi, A. J., Shorbagi, A. I., & Saber-Ayad, M. (2024). From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1326776

Vancouver

Shubbar Q, Alchakee A, Issa KW, Adi AJ, Shorbagi AI, Saber-Ayad M. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1326776

BibTeX
@article{Shubbar2024,
  author = {Shubbar, Qamar and Alchakee, Aminah and Issa, Khaled Walid and Adi, Abdul Jabbar and Shorbagi, Ali Ibrahim and Saber-Ayad, Maha},
  title = {From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1326776}
}
Kostenlos starten →